Elicio Net Income vs Net Income Per E B T Analysis

ELTX Stock

5.62 0.48 9.34%

Elicio Therapeutics financial indicator trend analysis is much more than just examining Elicio Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Elicio Therapeutics is a good investment. Please check the relationship between Elicio Therapeutics Net Income and its Net Income Per E B T accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Net Income vs Net Income Per E B T

Net Income vs Net Income Per E B T Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Elicio Therapeutics Net Income account and Net Income Per E B T. At this time, the significance of the direction appears to have no relationship.

The correlation between Elicio Therapeutics' Net Income and Net Income Per E B T is 0.04. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Net Income Per E B T in the same time period over historical financial statements of Elicio Therapeutics, assuming nothing else is changed. The correlation between historical values of Elicio Therapeutics' Net Income and Net Income Per E B T is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Elicio Therapeutics are associated (or correlated) with its Net Income Per E B T. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per E B T has no effect on the direction of Net Income i.e., Elicio Therapeutics' Net Income and Net Income Per E B T go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Elicio Therapeutics financial statement analysis. It represents the amount of money remaining after all of Elicio Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Net Income Per E B T

Most indicators from Elicio Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Elicio Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elicio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.At this time, Elicio Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 10.3 M in 2025, whereas Sales General And Administrative To Revenue is likely to drop 0.29 in 2025.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	1.1M	1.2M	1.3M	828.2K
Interest Income	64.8K	373K	429.0K	450.4K

Depreciation And Amortization Interest Income

Elicio Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.71	0.69	0.66	0.31	-0.91	0.87	0.61	-0.01	-0.92	0.92	0.81	0.96	0.92	0.92	0.81	0.35	-0.75	-0.17	0.85	-0.1	0.91	0.89	-0.03	0.32	0.89
Short Long Term Debt Total	0.71		0.94	0.97	-0.03	-0.86	0.62	0.98	0.6	-0.8	0.71	0.43	0.76	0.85	0.52	0.43	-0.04	-0.97	0.06	0.6	0.29	0.75	0.91	0.25	0.04	0.65
Other Current Liab	0.69	0.94		0.98	0.21	-0.75	0.5	0.87	0.42	-0.76	0.7	0.57	0.66	0.79	0.46	0.57	0.0	-0.84	-0.2	0.5	0.24	0.69	0.78	-0.01	0.28	0.54
Total Current Liabilities	0.66	0.97	0.98		0.03	-0.77	0.45	0.94	0.49	-0.73	0.66	0.52	0.64	0.83	0.45	0.52	0.07	-0.89	-0.02	0.46	0.17	0.66	0.82	0.18	0.11	0.49
Total Stockholder Equity	0.31	-0.03	0.21	0.03		-0.17	0.22	-0.2	-0.51	-0.38	0.5	0.49	0.18	0.06	0.33	0.49	-0.1	0.07	-0.98	0.39	0.16	0.41	-0.04	-0.96	1.0	0.22
Net Tangible Assets	-0.91	-0.86	-0.75	-0.77	-0.17		-0.86	-0.8	-0.31	0.98	-0.92	-0.58	-0.95	-0.92	-0.86	-0.58	-0.12	0.93	0.05	-0.89	-0.15	-0.96	-0.96	-0.11	-0.2	-0.88
Property Plant And Equipment Net	0.87	0.62	0.5	0.45	0.22	-0.86		0.52	0.22	-0.85	0.81	0.44	0.96	0.71	0.81	0.44	-0.04	-0.72	-0.07	0.92	0.25	0.87	0.81	0.02	0.2	1.0
Current Deferred Revenue	0.61	0.98	0.87	0.94	-0.2	-0.8	0.52		0.68	-0.71	0.61	0.32	0.68	0.81	0.45	0.32	-0.01	-0.96	0.23	0.51	0.25	0.66	0.88	0.41	-0.14	0.55
Net Debt	-0.01	0.6	0.42	0.49	-0.51	-0.31	0.22	0.68		-0.18	0.01	-0.45	0.21	0.16	-0.19	-0.45	-0.59	-0.58	0.45	0.12	0.68	0.14	0.4	0.54	-0.46	0.23
Retained Earnings	-0.92	-0.8	-0.76	-0.73	-0.38	0.98	-0.85	-0.71	-0.18		-0.98	-0.65	-0.93	-0.88	-0.88	-0.65	-0.09	0.85	0.26	-0.92	-0.17	-0.98	-0.9	0.11	-0.4	-0.87
Accounts Payable	0.92	0.71	0.7	0.66	0.5	-0.92	0.81	0.61	0.01	-0.98		0.73	0.89	0.84	0.91	0.73	0.16	-0.77	-0.37	0.93	0.1	0.99	0.83	-0.23	0.52	0.83
Cash	0.81	0.43	0.57	0.52	0.49	-0.58	0.44	0.32	-0.45	-0.65	0.73		0.61	0.76	0.76	1.0	0.66	-0.39	-0.39	0.48	-0.48	0.62	0.56	-0.28	0.51	0.47
Non Current Assets Total	0.96	0.76	0.66	0.64	0.18	-0.95	0.96	0.68	0.21	-0.93	0.89	0.61		0.88	0.88	0.61	0.16	-0.83	-0.03	0.91	0.1	0.93	0.93	0.1	0.18	0.97
Non Currrent Assets Other	0.92	0.85	0.79	0.83	0.06	-0.92	0.71	0.81	0.16	-0.88	0.84	0.76	0.88		0.84	0.76	0.44	-0.87	0.05	0.71	-0.17	0.83	0.95	0.22	0.1	0.74
Other Assets	0.92	0.52	0.46	0.45	0.33	-0.86	0.81	0.45	-0.19	-0.88	0.91	0.76	0.88	0.84		0.76	0.45	-0.64	-0.16	0.88	-0.22	0.9	0.79	-0.05	0.32	0.82
Cash And Short Term Investments	0.81	0.43	0.57	0.52	0.49	-0.58	0.44	0.32	-0.45	-0.65	0.73	1.0	0.61	0.76	0.76		0.66	-0.39	-0.39	0.48	-0.48	0.62	0.56	-0.28	0.51	0.47
Net Receivables	0.35	-0.04	0.0	0.07	-0.1	-0.12	-0.04	-0.01	-0.59	-0.09	0.16	0.66	0.16	0.44	0.45	0.66		0.01	0.2	-0.03	-0.96	0.07	0.2	0.21	-0.11	-0.02
Common Stock Shares Outstanding	-0.75	-0.97	-0.84	-0.89	0.07	0.93	-0.72	-0.96	-0.58	0.85	-0.77	-0.39	-0.83	-0.87	-0.64	-0.39	0.01		-0.15	-0.73	-0.27	-0.82	-0.96	-0.33	0.03	-0.74
Non Current Liabilities Total	-0.17	0.06	-0.2	-0.02	-0.98	0.05	-0.07	0.23	0.45	0.26	-0.37	-0.39	-0.03	0.05	-0.16	-0.39	0.2	-0.15		-0.25	-0.22	-0.28	0.15	0.98	-0.99	-0.08
Capital Lease Obligations	0.85	0.6	0.5	0.46	0.39	-0.89	0.92	0.51	0.12	-0.92	0.93	0.48	0.91	0.71	0.88	0.48	-0.03	-0.73	-0.25		0.26	0.96	0.79	-0.14	0.39	0.93
Inventory	-0.1	0.29	0.24	0.17	0.16	-0.15	0.25	0.25	0.68	-0.17	0.1	-0.48	0.1	-0.17	-0.22	-0.48	-0.96	-0.27	-0.22	0.26		0.19	0.07	-0.19	0.17	0.24
Other Current Assets	0.91	0.75	0.69	0.66	0.41	-0.96	0.87	0.66	0.14	-0.98	0.99	0.62	0.93	0.83	0.9	0.62	0.07	-0.82	-0.28	0.96	0.19		0.87	-0.13	0.42	0.89
Other Stockholder Equity	0.89	0.91	0.78	0.82	-0.04	-0.96	0.81	0.88	0.4	-0.9	0.83	0.56	0.93	0.95	0.79	0.56	0.2	-0.96	0.15	0.79	0.07	0.87		0.32	-0.01	0.84
Total Liab	-0.03	0.25	-0.01	0.18	-0.96	-0.11	0.02	0.41	0.54	0.11	-0.23	-0.28	0.1	0.22	-0.05	-0.28	0.21	-0.33	0.98	-0.14	-0.19	-0.13	0.32		-0.95	0.02
Net Invested Capital	0.32	0.04	0.28	0.11	1.0	-0.2	0.2	-0.14	-0.46	-0.4	0.52	0.51	0.18	0.1	0.32	0.51	-0.11	0.03	-0.99	0.39	0.17	0.42	-0.01	-0.95		0.21
Property Plant And Equipment Gross	0.89	0.65	0.54	0.49	0.22	-0.88	1.0	0.55	0.23	-0.87	0.83	0.47	0.97	0.74	0.82	0.47	-0.02	-0.74	-0.08	0.93	0.24	0.89	0.84	0.02	0.21

Click cells to compare fundamentals

Elicio Therapeutics Account Relationship Matchups

Elicio Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	19.7M	14.8M	22.7M	27.1M	31.2M	20.5M
Short Long Term Debt Total	439.4K	11.8M	7.5M	6.9M	8.0M	6.1M
Other Current Liab	1.2M	5.4M	1.9M	3.8M	4.4M	3.0M
Total Current Liabilities	3.3M	18.9M	6.9M	9.8M	11.2M	8.9M
Total Stockholder Equity	(49.1M)	(74.5M)	(102.1M)	11.4M	13.1M	13.7M
Property Plant And Equipment Net	1.0M	890.4K	8.5M	7.3M	8.4M	4.2M
Current Deferred Revenue	(439.4K)	2.4M	1.4M	694K	798.1K	816.3K
Net Debt	(14.5M)	2.5M	1.3M	(6.0M)	(6.9M)	(7.2M)
Retained Earnings	(52.4M)	(78.8M)	(107.0M)	(142.2M)	(128.0M)	(134.4M)
Accounts Payable	1.7M	1.7M	2.8M	4.4M	5.0M	5.3M
Cash	15.0M	9.3M	6.2M	12.9M	14.8M	11.0M
Non Current Assets Total	4.2M	4.5M	11.9M	10.8M	12.4M	7.3M
Non Currrent Assets Other	2.4M	2.8M	2.8M	2.8M	3.3M	2.2M
Cash And Short Term Investments	15.0M	9.3M	6.2M	12.9M	14.8M	11.0M
Liabilities And Stockholders Equity	19.7M	14.8M	22.7M	27.1M	31.2M	20.5M
Non Current Liabilities Total	65.5M	70.5M	117.9M	6.0M	5.4M	5.1M
Capital Lease Obligations	439.4K	0.0	7.5M	6.9M	8.0M	8.4M
Other Current Assets	486.0K	1.1M	2.9M	3.5M	4.0M	4.2M
Other Stockholder Equity	69.1M	160.2M	222.3M	153.7M	176.7M	133.6M
Total Liab	68.8M	89.4M	124.8M	15.8M	18.1M	17.2M
Net Invested Capital	(49.1M)	(62.7M)	(102.1M)	11.4M	13.1M	13.7M
Property Plant And Equipment Gross	1.5M	1.6M	9.6M	8.5M	9.8M	5.1M
Total Current Assets	15.5M	10.4M	10.7M	16.3M	18.8M	13.2M
Accumulated Other Comprehensive Income	(507.4K)	(103K)	(111.1M)	(197K)	(177.3K)	(186.2K)
Capital Stock	130.6K	171.4K	177.0K	96K	110.4K	135.2K
Net Working Capital	12.1M	(8.5M)	3.8M	6.6M	5.9M	3.1M
Short Term Debt	439.4K	11.8M	692K	910K	1.0M	994.2K
Common Stock	130.6K	171.4K	177.0K	96K	110.4K	135.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Elicio Net Income vs Net Income Per E B T Analysis

Net Income vs Net Income Per E B T

Net Income vs Net Income Per E B T Correlation Analysis

Correlation Coefficient

Net Income

Net Income Per E B T

Elicio Therapeutics fundamental ratios Correlations

Elicio Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Elicio Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Elicio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Other Current Assets	+ 0.99	Accounts Payable
Current Deferred Revenue	+ 0.98	Short Long Term Debt Total
Total Current Liabilities	+ 0.98	Other Current Liab

Net Invested Capital	- 0.99	Non Current Liabilities Total
Other Current Assets	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.98	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.97	Short Long Term Debt Total
Other Stockholder Equity	- 0.96	Common Stock Shares Outstanding